News & Updates
Showing Respirology articles
Showing

Sacituzumab govitecan plus pembrolizumab no better than monotherapy in metastatic NSCLC
Combination treatment with sacituzumab govitecan (SG) and pembrolizumab has resulted in a numerically longer progression-free survival (PFS) compared with pembrolizumab alone in patients with previously untreated metastatic nonsmall-cell lung cancer (NSCLC), but the difference did not reach statistical significance, according to the phase III EVOKE-03/KEYNOTE D46 study.

ARTEMIS-008: Risvutatug rezetecan shows promise as new standard of care for relapsed SCLC
Treatment with the B7-H3-directed antibody-drug conjugate risvutatug rezetecan (Ris-Rez) results in significant improvements in overall survival (OS) compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) who had progressed after receiving platinum-based chemotherapy, as shown by the results of the phase III ARTEMIS-008 trial.

MAD not inferior to CPAP in improving cardiovascular health of OSA patients
A recent study has shown the noninferiority of mandibular advancement device (MAD) to continuous positive airway pressure (CPAP) for reducing 24-h mean arterial blood pressure (BP) at 1 year among individuals with hypertension and increased cardiovascular risk.

PAPILLON reports longest OS in EGFR ex20ins NSCLC with amivantamab–chemo
First-line (1L) amivantamab plus chemotherapy improves overall survival (OS) in patients with treatment-naïve, locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations, according to the results from the protocol-specified final OS analysis of the phase III PAPILLON study.




